Please login to the form below
Sparsentan
This page shows the latest Sparsentan news and features for those working in and with pharma, biotech and healthcare.
Retrophin rockets away as rare disease trial hits targets
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Sparsentan was brought into Retrophin's pipeline
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
- Man vs microbe: the fight against antimicrobial resistance
- Dollo's law
No results were found
PMHub
fox&cat
Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...
Latest intelligence
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
- HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
- In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....
